MedPath

The Effect of Nitroglycerine on Microcirculatory Abnormalities During Sepsis

Phase 3
Completed
Conditions
Sepsis
Septic Shock
Interventions
Drug: placebo = nacl 0.9%
Registration Number
NCT00493415
Lead Sponsor
Medical Centre Leeuwarden
Brief Summary

The purpose of this study is to evaluate the effect of nitro-glycerine on the microcirculation (smallest vessel type) in patients with severe sepsis and septic shock.

Nitro-glycerine is a well known medicine in cardiology and is used to improve circulation. In this ICU the investigators use nitro-glycerine to improve the organ perfusion; but it's no common therapy in the rest of the world. The investigators now compare nitro-glycerine and placebo by looking to the sublingual microcirculation by a small camera (SDF imaging).

Detailed Description

This study starts at admission of the patient on the ICU. In the next 24 hours the patient receives nitro-glycerine or placebo (randomised). At time = 0, ½, 2, 12 and 24 hour we evaluate the microcirculation by SDF imaging and monitoring of hemodynamic parameters.

Informed consent is obtained of the relatives.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Severe sepsis
  • Proven infection
  • Informed consent
Exclusion Criteria
  • Age < 18 years
  • Pregnancy
  • Use of nitroglycerine within 24 hours prior to ICU admittance
  • Necessity to use nitroglycerine iv for instable angina

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1nitroglycerin ivnitroglycerine iv
2placebo = nacl 0.9%nacl 0.9% 4 ml/h iv in the first 30 minutes, 2 ml/h iv in the next 23 hours and 30 minutes
Primary Outcome Measures
NameTimeMethod
increase of MFI by nitro-glycerine2 years
Secondary Outcome Measures
NameTimeMethod
decrease of length of stay decrease of SOFA decrease of morbidity/mortality2 years

Trial Locations

Locations (1)

Medical Centre Leeuwarden - Intensive Care Unit

🇳🇱

Leeuwarden, Netherlands

© Copyright 2025. All Rights Reserved by MedPath